BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Conference / presentation

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C.

Related news

MISTMilestone Pharmaceuticals Inc.2026-04-07 12:30 EST

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

MISTMilestone Pharmaceuticals Inc.2026-03-16 12:13 EST

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

LXRXLexicon Pharmaceuticals2026-05-12 12:30 EST

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

SGMTSagimet Biosciences2026-05-13 11:00 EST

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

VANIVivani Medical2026-07-14 20:03 EST

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

SGMTSagimet Biosciences2026-06-23 00:49 EST

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RYTMRhythm Pharmaceuticals2026-05-29 12:00 EST

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal supraventricular tachycardia to sinus rhythm. Atrial Fibrillation...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Stock data

Close
1.18 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States